Christian Grov1,2, Drew Westmoreland1, Corey Morrison1, Adam W Carrico3, Denis Nash1,2. 1. CUNY Institute for Implementation Science in Population Health, New York, NY. 2. CUNY Graduate School of Public Health and Health Policy, New York, NY; and. 3. Department of Public Health Sciences, University of Miami, Miami, FL.
Abstract
INTRODUCTION: Methamphetamine use is once again on the rise among sexual and gender minorities who have sex with men (SGMSM). METHODS: Baseline and 12-month data are taken from an ongoing cohort study of n = 4786 SGMSM aged 16-49 at risk for HIV from across the United States. Participants completed annual online surveys and at-home HIV testing (oral fluid samples returned through mail). RESULTS: Overall, 2.47 per 100 persons seroconverted over 12 months. In addition, 13.8% of participants reported any methamphetamine use over the 12-month study period. Nearly three-fourths (74.7%; 422 of 565) of those who reported using methamphetamine at baseline were persistent users at 12 months. In adjusted analyses, compared with those who did not use methamphetamine, incident methamphetamine users (ie, those who indicated use between baseline and follow-up) and persistent methamphetamine users had significantly higher odds of HIV seroconverting (adjusted odds ratio = 3.95, 95% confidence interval: 1.64 to 9.47; and 7.11, 4.53 to 11.17, respectively). Persistent methamphetamine users accounted for one-third of all observed HIV seroconversions (41 of 115). DISCUSSION: Among SGMSM at elevated risk for HIV, persistent methamphetamine use was prevalent and associated with substantially amplified risk for HIV seroconversion. Expanded efforts are needed to test implementation strategies for scalable, evidence-based interventions to reduce HIV risk in SGMSM who use methamphetamine.
INTRODUCTION:Methamphetamine use is once again on the rise among sexual and gender minorities who have sex with men (SGMSM). METHODS: Baseline and 12-month data are taken from an ongoing cohort study of n = 4786 SGMSM aged 16-49 at risk for HIV from across the United States. Participants completed annual online surveys and at-home HIV testing (oral fluid samples returned through mail). RESULTS: Overall, 2.47 per 100 persons seroconverted over 12 months. In addition, 13.8% of participants reported any methamphetamine use over the 12-month study period. Nearly three-fourths (74.7%; 422 of 565) of those who reported using methamphetamine at baseline were persistent users at 12 months. In adjusted analyses, compared with those who did not use methamphetamine, incident methamphetamine users (ie, those who indicated use between baseline and follow-up) and persistent methamphetamine users had significantly higher odds of HIV seroconverting (adjusted odds ratio = 3.95, 95% confidence interval: 1.64 to 9.47; and 7.11, 4.53 to 11.17, respectively). Persistent methamphetamine users accounted for one-third of all observed HIV seroconversions (41 of 115). DISCUSSION: Among SGMSM at elevated risk for HIV, persistent methamphetamine use was prevalent and associated with substantially amplified risk for HIV seroconversion. Expanded efforts are needed to test implementation strategies for scalable, evidence-based interventions to reduce HIV risk in SGMSM who use methamphetamine.
Authors: Teresa A Chueng; Hansel E Tookes; Megan McLaughlin; Angela M Arcaro-Vinas; David P Serota; Tyler S Bartholomew Journal: Subst Use Misuse Date: 2022-06-10 Impact factor: 2.362
Authors: Brian W Weir; Chen Dun; Andrea L Wirtz; Sandra Hsu Hnin Mon; Noor Qaragholi; Tareerat Chemnasiri; Sarika Pattanasin; Wichuda Sukwicha; Anchalee Varangrat; Eileen F Dunne; Timothy H Holtz; Surang Janyam; Harry Jin; Danai Linjongrat; Philip A Mock; Michael C Thigpen; James F Rooney; Patrick S Sullivan; Andrew C Hickey; Pachara Sirivongrangson; Chris Beyrer Journal: Ann Epidemiol Date: 2022-04-08 Impact factor: 6.996
Authors: Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico Journal: Curr HIV/AIDS Rep Date: 2022-06-14 Impact factor: 5.495
Authors: Gregory L Greenwood; Amber Wilson; Geetha P Bansal; Christopher Barnhart; Elizabeth Barr; Rick Berzon; Cheryl Anne Boyce; William Elwood; Joyonna Gamble-George; Mary Glenshaw; Rebecca Henry; Hiroko Iida; Richard A Jenkins; Sonia Lee; Arianne Malekzadeh; Kathryn Morris; Peter Perrin; Elise Rice; Meryl Sufian; Darien Weatherspoon; Miya Whitaker; Makeda Williams; Sheryl Zwerski; Paul Gaist Journal: AIDS Behav Date: 2021-04-22